Home/Filings/4/0001567619-18-003533
4//SEC Filing

Clarus Lifesciences III, L.P. 4

Accession 0001567619-18-003533

CIK 0001656634other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 5:20 PM ET

Size

15.2 KB

Accession

0001567619-18-003533

Insider Transaction Report

Form 4
Period: 2018-09-28
Transactions
  • Purchase

    Common Stock

    2018-09-28$15.00/sh+333,333$4,999,995333,333 total
  • Conversion

    Common Stock

    2018-10-02+2,234,1122,567,445 total
  • Conversion

    Series A Convertible Preferred Stock

    2018-10-021,565,2160 total
    Common Stock (1,565,216 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2018-10-02668,8960 total
    Common Stock (668,896 underlying)
Footnotes (3)
  • [F1]Clarus Ventures III GP, L.P. ("GPLP"), as the sole GP of the Reporting Person, may be deemed to beneficially own certain shares held by the Reporting Person. The GPLP disclaims beneficial ownership of all shares held by the Reporting Person in which the GPLP does not have pecuniary interest. Clarus Ventures III, LLC ("GPLLC"), as the sole GP of the GPLP, may be deemed to beneficially own certain of the shares held by the Reporting Person. The GPLLC disclaims beneficial ownership of all shares held by the Reporting Person in which it does not have pecuniary interest. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as managing directors of the GPLLC, may be deemed to beneficially own certain shares held by the Reporting Person. Each of Messrs. Galakatos, Henner, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by the Reporting Person in which he does not have pecuniary interest.
  • [F2]The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
  • [F3]The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Documents

1 file

Issuer

Gritstone Oncology, Inc.

CIK 0001656634

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001597143

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 5:20 PM ET
Size
15.2 KB